Enabling the immune system to fight cancer

Successful initial public offering on Oslo Børs / Stock Exchange. First day of trading 03.06.2019.

Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.

Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.